Jolien Tol

Jolien Tol

Auto-generated profile, based on publicly available information

Jolien Tol

Department of Medical Oncology, Jeroen Bosch Ziekenhuis, Henri Dunantstraat 1, 5223 GZ, 'S-Hertogenbosch, The Netherlands

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 March 2023 in Breast Cancer Research and Treatment
Verified
Journal Article
Closed access
PDF file
AHAnnemiek K E van Hemert
Annemiek K E van Hemert
JOJosefien P van Olmen
Josefien P van Olmen
LBLiesbeth J. Boersma
Liesbeth J. Boersma
JMJohn H. Maduro
John H. Maduro
NRNicola S Russell
Nicola S Russell
FDFrederieke H van Duijnhoven
Frederieke H van Duijnhoven

19 May 2020 in BMJ Supportive & Palliative Care
Verified
Journal Article
Closed access
PDF file
SRStefan G. van Ravensteijn
Stefan G. van Ravensteijn
BMBritt van Merrienboer
Britt van Merrienboer
SAStefan van Asten
Stefan van Asten
JPJohannes Pruijt
Johannes Pruijt
MHMirrian Hilbink
Mirrian Hilbink
JTJolien Tol
Jolien Tol
Objective Oxaliplatin is a cytotoxic agent frequently used in the treatment of gastrointestinal cancer patients. A known side effect of oxaliplatin administration via a peripheral vein is infusion-related pain. In this retrospective cohort study we compared the incidence of infusion-related pain in patients treated with oxaliplatin with or without simultaneous fluid infusion (FI) (800 mL glucose 5% in 2 hours). Methods We retrospectively defined two cohorts: Patients treated with oxaliplatin and simultaneous intravenous FI and the same number of patients treated without FI. The incidence of infusion-related venous pain was the primary outcome measure. Secondary outcomes included: Incidence of hypersensitivity reactions, infusion time, dose density, number of patients switched to a central venous catheter and incidence of peripheral neuropathy. Results 100 patients were included, 50 patients in both groups. Baseline characteristics were comparable, except for age (median 66.8 vs 62.4 years in groups with and without FI; p=0.017), and body mass index (28.0 vs 25.7 kg/m2, respectively; p=0.012). Patients treated with simultaneous FI experienced significantly less vascular pain compared with those without FI (10% vs 78%, respectively; p<0.0001; OR 0.031 (95% CI: 0.01 to 0.098)). No difference was observed in dose density, treatment delay or the need of central venous catheter. Logistic regression analysis showed no confounders affecting the primary outcome. No adverse events of FI were observed. Conclusion Concurrent infusion of 800 mL glucose 5% with peripheral venous administration of oxaliplatin significantly reduces the incidence of infusion-related pain in gastrointestinal cancer patients and is highly feasible and affordable in everyday clinical practice.